These six CARs exhibited cytotoxicity against CD33+ AML cell lines in vitro and in vivo and showed strong anti-leukemia activity against patient-derived xenograft (PDX) derived from pediatric AML patients. The gene discussed is CD33; the disease is acute myeloid leukemia.